Medicofarma Biotech SA (WSE:MDB)
Poland · Delayed Price · Currency is PLN 0.4500
0.00 (0.00%)
At close: Jun 5, 2026
Medicofarma Biotech Income Statement
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.04 | 0.12 | 1.22 | 0.75 | 4.25 | 3.34 | |
Revenue Growth (YoY) | -90.55% | -90.21% | 63.14% | -82.34% | 27.45% | -8.59% |
Cost of Revenue | 1.01 | 1.22 | 1.48 | 0.96 | 3.73 | 2.35 |
Gross Profit | -0.97 | -1.1 | -0.26 | -0.21 | 0.53 | 0.99 |
Selling, General & Admin | 0.13 | 0.14 | 0.24 | 0.32 | 0.35 | 0.31 |
Other Operating Expenses | -0.94 | -0.94 | 0.03 | 0.12 | 0.01 | 0.01 |
Operating Expenses | 0.58 | 0.6 | 1.82 | 2.42 | 2.1 | 1.27 |
Operating Income | -1.55 | -1.7 | -2.07 | -2.63 | -1.58 | -0.28 |
Interest Expense | -0.62 | -0.62 | -0.24 | -0.17 | -0.01 | -0.01 |
Other Non Operating Income (Expenses) | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.03 |
EBT Excluding Unusual Items | -2.18 | -2.33 | -2.32 | -2.81 | -1.59 | -0.33 |
Impairment of Goodwill | 0.1 | 0.1 | - | 0.1 | - | - |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.04 |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 0.07 |
Asset Writedown | - | - | - | -0.94 | - | - |
Pretax Income | -2.08 | -2.23 | -2.32 | -3.65 | -1.59 | -0.22 |
Income Tax Expense | - | - | -0.02 | -0.21 | - | - |
Net Income | -2.08 | -2.23 | -2.3 | -3.44 | -1.59 | -0.22 |
Net Income to Common | -2.08 | -2.23 | -2.3 | -3.44 | -1.59 | -0.22 |
Shares Outstanding (Basic) | - | 68 | 68 | 68 | 68 | 68 |
Shares Outstanding (Diluted) | - | 68 | 68 | 68 | 68 | 68 |
Shares Change (YoY) | - | - | - | - | - | 901.99% |
EPS (Basic) | - | -0.03 | -0.03 | -0.05 | -0.02 | -0.00 |
EPS (Diluted) | - | -0.03 | -0.03 | -0.05 | -0.02 | -0.00 |
Free Cash Flow | -0.94 | -0.98 | -1.02 | -1.1 | -0.25 | -0.48 |
Free Cash Flow Per Share | - | -0.01 | -0.01 | -0.02 | -0.00 | -0.01 |
Gross Margin | - | - | -21.07% | -27.80% | 12.35% | 29.64% |
Operating Margin | -3529.54% | -1418.73% | -169.34% | -350.57% | -37.07% | -8.53% |
Profit Margin | -4736.04% | -1860.32% | -187.82% | -458.07% | -37.38% | -6.45% |
Free Cash Flow Margin | -2141.71% | -820.32% | -83.23% | -146.38% | -5.83% | -14.48% |
EBITDA | -0.06 | -0.21 | -0.53 | -0.55 | 0.17 | 0.67 |
EBITDA Margin | -129.01% | -173.66% | -42.94% | -72.92% | 4.04% | 19.97% |
D&A For EBITDA | 1.49 | 1.49 | 1.55 | 2.08 | 1.75 | 0.95 |
EBIT | -1.55 | -1.7 | -2.07 | -2.63 | -1.58 | -0.28 |
EBIT Margin | - | - | -169.34% | - | -37.07% | -8.53% |
Revenue as Reported | 0.04 | 0.12 | 1.22 | 0.75 | 4.25 | 3.34 |